Replimune Group, Inc. Board of Directors

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Mr. Andrew Schwendenman

Mr. Andrew Schwendenman

Chief Accounting Officer & Treasurer

Mr. Christopher Sarchi

Mr. Christopher Sarchi

Chief Commercial Officer

Dr. Robert Coffin Ph.D.

Dr. Robert Coffin Ph.D.

Founder, Chief Scientist & Director

Ms. Emily Luisa Hill

Ms. Emily Luisa Hill

Chief Financial Officer

Mr. Paul Bullock

Mr. Paul Bullock

Chief Manufacturing Officer & Framingham Site Head

Comments